Since early this year, the Obama administration has been shifting money around to cover the costs of the work being done by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the FDA and other federal agencies to address the Zika crisis in the Americas and to prepare the US for the invasion of the virus.
Since early this year, the Obama administration has been shifting money around to cover the costs of the work being done by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the FDA and other federal agencies to address the Zika crisis in the Americas and to prepare the US for the invasion of the virus.
But now, the sources of those funds have dried up and because the Republican-controlled Congress has been reluctant to grant...
Swiss major confident that new oncology drugs will fill revenue gap.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
Multi-blockbuster falls short in a giant cell arteritis study.
Bharatt Chowrira departs days after firm’s chair stepped down.
Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
